Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Companion Animal Vaccines Market Outlook (2023 to 2033)

Future Market Insights, Inc researchers have pointed out that the global companion animal vaccines market is expected to register a CAGR of 6.8% from 2023 to 2033. The market is expected to cross an estimated US$ 6.7 billion by 2033. As of 2023, the market is estimated at US$ 3.4 billion.

Some factors expected to surge the market growth are:

  • Humanization of pets.
  • Growing awareness regarding pet insurance.
  • Increase in the number of cases pertaining to animal diseases.

Routine vaccine programs for companion animals have eliminated some chronic scourges in developed countries. The improved focus on vaccination campaigns and higher awareness for pet care are fueling the demand for companion animal vaccines. The veterinary healthcare industry is witnessing increased demand for protozoan parasitic vaccines from countries in tropical and subtropical regions.

The development of resistance to various chemotherapeutic agents is contributing to increased demand for vaccines over anti-parasitic drugs. In this regard, scientists have noted that the production of third-generation DNA vaccines against protozoan parasites could prove essentially helpful. These vaccines are safe as they do not contain any pathogens. Moreover, these are more stable compared to live attenuated and killed viruses in the vaccine and cost-effective.

Another reason for the surge in the market includes increased awareness about zoonotic diseases and government initiatives to curb anti-microbial resistance among pets. The industry is also driven by rising awareness regarding animal diseases and technological advancements in the biotechnology market. For example, during the COVID-19 pandemic, there were vaccines that were launched for animals, like Ancovax and Carnivac-Cov. The vaccine has been developed by Rosselkhoznadzor, which is based out in Russia. Additionally, the government of India launched the CAN-CoV-2 ELISA kit, which detects COVID in canines.

There are also various government initiatives that might surge the demand for companion animal vaccines. The National Institute of Food and Agriculture in the United States of America invested over US$ 13 million in March 2022 for treating and eradicating livestock diseases. The institute had announced 24 grants as a part of its plan.

Numerous people are wary of the fact that diseases from animals can be transmitted to human beings. Diseases like parvovirus, neoplasia and rhinotracheitis are caused because of animal bites. Therefore, a lot of owners are getting their pets vaccinated. These factors are expected to surge the sales of companion animal vaccines during the forecast period. However, factors such as difficulties in understanding the epidemiology of veterinary diseases and high costs might hamper the discovery and production limit for a vaccine.

Europe is expected to be a key market during the forecast period. The key manufacturers based out in the region are investing massive amounts in the R&D process. Based on a study, France has nearly 17 dogs per 100 people, which shows the enormous potential that the region has. North America closely follows Europe.

Attributes Value
Companion Animal Vaccines Market Value (2022) US$ 3.2 billion
Companion Animal Vaccines Market Value (2023) US$ 3.4 billion
Companion Animal Vaccines Market Forecast Value (2033) US$ 6.7 billion
Companion Animal Vaccines Market Expected CAGR (2023 to 2033) 6.8%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Analyzing Historical CAGR (2017 to 2022) vs Anticipated CAGR (2023 to 2033)

A growing number of pets around the world and increasing awareness of the importance of pet vaccination can be attributed to the growth of this market. According to the North American Pet Health Insurance Association, approximately 2.2 million pets in the United States of America were covered by health insurance in the year 2018. These figures were 18% more than the numbers recorded in the previous year.

Pet insurance acts as a decision-maker in the companion animal health value chain, including third-party payers. The increasing pet insurance coverage in the United States of America and other developed countries is expected to act as a value driver to the market. Even the comparison between historical CAGR and anticipated CAGR displays positive trends ahead. While the historical CAGR for the market was 5.9%, the anticipated CAGR is 6.8%.

  • Short-term (2023 to 2026): During this period, we might witness governments around the world encouraging pet owners to vaccinate their pets. They might also warn against the unnecessary use of antibiotics for their treatment since there is an increased prevalence of antimicrobial resistance amongst companion animals. Veterinary vaccines reduce reliance on anthelmintic and antimicrobial drugs for treating infections. This may lead to demand for preventive healthcare tools such as booster vaccines for companion animals.
  • Medium-term (2026 to 2029): With a surge in the number of companion animals, the demand for companion animal vaccines is expected to grow. The COVID-19 pandemic led to many households adopting pets during the lockdown phase. The American Pet Products Association conducted a COVID-19 Pulse Study”, which concluded that around 11.3 million households in the United States of America got a new pet during the pandemic. These numbers are expected to sky-rocket.
  • Long-term (2029 to 2033): During this period, we might witness a lot of steps being taken by the key players. The key players in this industry might focus on external partnerships in research, driving vaccine development. They might also enter into collaborative partnerships and acquisitions to expand their businesses worldwide.

For instance, in August 2020, Elanco Animal Health Inc. announced the acquisition of the Bayer Animal Health segment. This acquisition enabled Elanco to utilize Bayer’s product range to its full potential during the pandemic by offering the products through different sales channels.

In February 2021, Vetoquinol S.A. announced the acquisition of Profender®, which is a spot-on de-wormer product line’s intellectual property rights. The deals also included registration and other rights from Elanco Animal Health business in Canada, which was approved by the Canadian Competition Bureau. Thus, we may see a lot more such initiatives during this period.

What are the Key Opportunities for Manufacturers?

Merger & acquisition activities are gaining a wider footprint within the companion animal vaccines market in developed regions. This might widen product availability and easy market access. For instance, Elanco Animal Health acquired Kindred Biosciences in August 2021 to expand its product portfolio of dermatology in veterinary medicine. The focus is also on the unmet needs of pet owners and veterinarians.

Many companion animals are relinquished to shelters every year. Due to the increasing growth of companion animals, sterilization is an important process to control overpopulation. This provides an opportunity for companion animal vaccine manufacturers to come up with sterilization vaccines with safety and efficacy.

The increasing awareness of pet vaccination and zoonotic diseases, along with an increased number of pet ownerships, provide the manufacturers of this industry lucrative opportunities.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Restraining Factors for the Market?

Veterinarians have traditionally been responsible for the majority of the share of the companion animal vaccines market. This share of sales declined in the United States of America between 2004 and 2014. The shift moved fast with the introduction of the Fairness to Pet Owners Act in the United States of America Senate in May 2015. This act only allows vets to write prescriptions and allows owners to buy medicine and vaccines from retailers or pharmacies.

This change requires the companion animal vaccine players to change their strategies of targeting vets and shift to other important stakeholders. This shift is expected to divert the traditional revenue distribution and veterinary clinic consolidation resulting in affecting the profit margin distribution.

There exists a large gap in understanding the epidemiology pattern of veterinary diseases due to variations in disease patterns for endemic countries. A typical example is for Newcastle Disease for poultry and other birds, where the lack of epidemiological knowledge creates a serious economic loss.

Virulent Newcastle disease virus (vNDV) is evolving simultaneously at different locations due to isolates that are distributed worldwide and mutate rapidly. This leads to large knowledge gaps in the development of multiple vNDV genotypes. This hampers the discovery and production limit for a vaccine to prevent the spread of the disease. Recurrent infection in birds allows the maintenance of a reservoir for the viruses.

Comparative View for Companion Animal Vaccines Market

Companion Animal Vaccines Market:

Attributes Companion Animal Vaccines Market
Anticipated CAGR (2023 to 2033) 6.8%
Market Value (2023) US$ 3.4 billion
Growth Factor Humanization of pets
Future Opportunities Surging awareness regarding pet insurance
Market Trends The market is witnessing mergers and acquisitions

Fish Vaccines Market:

Attributes Fish Vaccines Market
Anticipated CAGR (2023 to 2033) 6.5%
Market Value (2023) US$ 0.23 billion
Growth Factor The surge in aquaculture farms
Future Opportunities Technological advancements in the market
Market Trends The market is experiencing a surge in passive immunization

Swine Vaccines Market:

Attributes Swine Vaccines Market
Anticipated CAGR (2023 to 2033) 5.8%
Market Value (2023) US$ 1.71 billion
Growth Factor The surge in demand for animal protein
Future Opportunities Rising investment in Research and Development
Market Trends Market suffering due to contagious diseases

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Country-wise Insights

Region North America
Country United States
CAGR (2023 to 2033) 7.9%
Region Europe
Country United Kingdom
CAGR (2023 to 2033) 5.5%
Region Asia Pacific
Country  China
CAGR (2023 to 2033) 7.4%
Region Asia Pacific
Country Japan
CAGR (2023 to 2033) , 6.7%
Region Asia Pacific
Country South Korea
CAGR (2023 to 2033) 4.9%

Will the United States of America remain a key companion animal vaccines market?

The United States of America held around 75.4% market share by revenue of the total market in North America in the year 2022. Availability of pet insurance, awareness of zoonotic diseases, and government initiatives to curb anti-microbial resistance amongst pets are some factors that might surge the share.

Attributes Details
United States of America Market Expected Size (2033) US$ 1.6 billion
United States of America Market Absolute Dollar Growth (US$ million/billion) US$ 864.2 million
CAGR % 2017 to 2022 5.4%

The United States of America is a country where there are a lot of cases pertaining to pet humanization. Apart from that, the presence of a lot of key players who are into developing pet vaccines makes the United States of America one of the key markets.

The United Kingdom Companion Animal Vaccines Market: Increasing Zoonotic Disease to Surge the Size

Based on research released, there are nearly 40 zoonotic diseases that exist in the United Kingdom As of 2022, nearly 3000,000 people were vulnerable to zoonotic diseases. An increase in the demand for imported rescue dogs has led to a significant increase in the number of such diseases. This has consequently led to an increase in the number of cases pertaining to leptospirosis, brucellosis, and tuberculosis.

Attributes Details
United Kingdom Market Expected Size (2033) US$ 253 million
United Kingdom Market Absolute Dollar Growth (US$ million/billion) US$ 104.4 million
CAGR % 2017 to 2022 6%

Apart from the surging demand for bio-secure packaging, the country has been witnessing an increase in the demand for companion animal vaccines. Moreover, with 1 in 2 households owning a pet in the United Kingdom, the application of animal vaccines is bound to increase in the coming times.

China Companion Animal Vaccines Market: Driven by Massive Number of Jabs for Cats and Dogs

The pet vaccinations market, which is a part of the pet market, is gradually becoming a mainstream market within itself. In February 2022, Shanghai-based Aichong Biotechnology announced that its feline-based vaccine had entered the clinical trial stage. Apart from that, Kanghua Biotech entered the high-end pet rabies vaccine segment.

Attributes Details
China Market Expected Size (2033) US$ 393.3 million
China Market Absolute Dollar Growth (US$ million/billion) US$ 201.2 million
CAGR % 2017 to 2022 7.8%

Based on a report released by the China Animal Agriculture Association, in 2021, pet inoculations topped the reason for pet visits to veterinarians. Nearly 70.3% of pet owners took their pets to hospitals at least once in 2022. These statistics reveal the scope of the companion animal vaccines market in China.

What is the Demand Outlook for Companion Animal Vaccines in Japan?

Japan is expected to face a massive adoption of companion animal vaccines. Japan has been witnessing an increase in the number of depression cases. In 2020, the number of depression cases rose to around 17.3%, which was a jump of more than 2% as compared to the previous year. Owing to this, a lot of psychiatrists and healthcare workers have suggested the adoption of pets. And the trend is shaping up.

Attributes Details
Japan Market Expected Size (2033) US$ 694.5 million
Japan Market Absolute Dollar Growth (US$ million/billion) US$ 331.5 million
CAGR % 2017 to 2022 4.6%

Based on a report in 2021, pet inoculations topped the reason for pet visits to veterinarians. Nearly 70.3% of pet owners took their pets to hospitals at least once in 2022. These statistics indeed reveal the scope of the companion animal vaccines market in China.

What is the Demand Outlook for Companion Animal Vaccines in Japan?

Japan is expected to face a massive adoption of companion animal vaccines. Japan has been witnessing an increase in the number of depression cases. In 2020, the number of depression cases rose to around 17.3%, which was a jump of more than 2% as compared to the previous year. Owing to this, a lot of psychiatrists and healthcare workers have suggested the adoption of pets. And the trend is shaping up.

Attributes Details
South Korea Market Expected Size (2033) US$ 234.2 million
South Korea Market Absolute Dollar Growth (US$ million/billion) US$ 89.2 million
CAGR % 2017 to 2022 5.4%

Owing to this, there has been a surge in the pet population in South Korea. This has consequently led to an increase in the sales of companion animal vaccines. Additionally, when the lockdowns were imposed, there was a massive surge in the adoption of pets to overcome loneliness.

Segmentation Insights

Segment Product Type
Attributes Attenuated Live Vaccines
CAGR % 2017 to 2022 6.6%
CAGR % 2023 to End of Forecast (2033) 6.9%
Segment Species Type
Attributes Canine
CAGR % 2017 to 2022 6.2%
CAGR % 2023 to End of Forecast (2033) 6.6%

Why is the demand for attenuated live vaccines a high by-product?

Live vaccines use attenuated (or weakened) forms of bacteria that cause the target disease. These vaccines are similar to natural infections in that they help prevent them by producing a strong, long-term immune response. Because of their high efficacy against all diseases, the demand for them is high. The sales of attenuated live vaccines are anticipated to be US$ 1.34 billion in the year 2023. Just 1 or 2 doses of attenuated live vaccines give lifetime protection against the germ, which is why the segment has gained a lot of traction.

Why is canine accounting for the maximum share by species type?

The sales for companion animal vaccines by the canine segment are expected to be US$ 1.96 billion in the year 2022. Canine is anticipated to hold 50.9% market share by revenue of the global market in 2022. According to the World Atlas pet ownership statistics, dogs are ranked first in the list of most popular pets in the United States of America, with approximately 48,255,413 households owning a pet dog as of August 2020. In the current times, pet owners are seeking faithful pets, and based on the theory of many psychologists, dogs are believed to be highly faithful. This factor is expected to surge the growth of this segment further.

Which distribution channel holds the maximum share in the companion animal vaccines market?

Veterinary clinics are expected to hold 43% market share by revenue of the global companion animal vaccines market in the year 2023. It is expected to record sales worth US$ 1.7 billion in the same year. Since the majority of pet owners prefer visiting a clinic for their pet’s vaccinations, this segment holds a high share of the market. Moreover, they are cost-efficient in comparison to hospitals. Furthermore, the accessibility factor is also one of the reasons why a lot of customers prefer to go to veterinary clinics.

Start-ups encapsulate Pharma Micro-particles in Polymer Shell

The start-ups operating in the market have developed a technology that encapsulates pharmaceutical micro-particles in a customizable polymer shell. This would assist in drug release extending from days to months. They are working on the existing drugs and making use of the injectable drug delivery platform, which would help in targeted therapies.

PetMedix: The start-up is based out in the United Kingdom. It has been developing monoclonal antibody therapeutics for pets. The start-up has developed Ky9 and Felyne platforms to generate therapeutic antibodies for treating inflammation and other conditions. In September 2021, PetMedix raised US$ 73 million in a Series B funding round.

Manufacturers focus on Radiology to broaden their Portfolio

The key players operating in the market are taking steps to advance the comprehensive Radiology portfolio. This happens along with the development pipeline of new contrast agents as well as more partnerships in the digital business. In November 2022, Bayer Healthcare advanced its Radiology development portfolio and made use of AI.

Some of the recent developments in the companion animal vaccines market are:

  • In November 2022, Bayer Healthcare acquired German biotech start-up Targenomix.
  • In November 2021, Felpreva, Vetoquinol’s new three-monthly feline parasiticide received marketing authorization from the European Commission.

The top companion animal vaccine manufacturers are:

Company Bayer Healthcare
Description Guided by the purpose of Science for a better life,’ Bayer has been delivering breakthrough innovations in healthcare and agriculture. The company has been contributing to a world in which diseases are not only treated but effectively prevented and cured. That is because Bayer, growth, and sustainability go hand in hand. Thus, the vision is ‘Health for all, hunger for none.’ Their robust strategy operationalizes their vision as the company looks to achieve long-term profitable growth and make a positive contribution to growth.
Company Boehringer Ingelheim
Description For Boehringer Ingelheim, the focus has always been on long-term performance. The company is working on breakthrough therapies that transform lives for generations to come. As a leading research-driven biopharma company, the company has been creating value through innovation. Boehringer Ingelheim currently employs more than 52,000 employees, who serve in more than 130 markets. The company is into human pharma, animal health medicine, and Biopharmaceutical Contract Manufacturing.
Company Ceva Santé Animale
Description Ceva Santé Animale has been helping veterinary professionals to achieve possible standards of animal health. The company researches, develops, manufactures, and supplies vaccines, along with equipment, training, and technical support. The business of the company mainly revolves around poultry, swine, ruminants, and companion animals. Ceva Santé Animale has been emphasizing its vision ‘Together, Beyond Animal Health’, which is all about people, animals, and the planet.

Companion Animal Vaccines Market Segmentation

By Product Type:

  • Attenuated Live Vaccines
  • Conjugate Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Toxoid Vaccines
  • DNA Vaccines
  • Recombinant Vaccines

By Distribution Channel:

  • Veterinary Clinics
  • Veterinary Hospitals
  • Veterinary Research Institutes
  • Retail Pharmacies

By Species Types:

  • Canine
  • Avian
  • Feline

By Region:

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • The Middle East and Africa (MEA)

Frequently Asked Questions

What Will be the Global Companion Animal Vaccines Market Value in Next Ten Years?

The global market could progress at 6.8% CAGR through 2033 concluding at US$ 6.7 billion.

Who are the Leading Players in the Global Companion Animal Vaccines Market?

Bayer Healthcare, and Boehringer Ingelheim are the top suppliers of companion animal vaccines.

Which Region is Considered most Favorable in the Market?

China is emerging as a lucrative market with an anticipated CAGR of 7.8% until 2033.

Which is Most Profitable Animal Category for Companion Animal Vaccines Market?

The canine segment generated US$ 1.96 billion which was 50.9% of the global revenue that year.

Which Type of Companion Animal Vaccines Dominates the Global Market?

Attenuated live vaccines segment dominates the market.

Table of Content

1. Executive Summary | Companion Animal Vaccines Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Product Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Product Type, 2017 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product Type, 2023 to 2033

        5.3.1. Attenuated Live Vaccines

        5.3.2. Conjugate Vaccines

        5.3.3. Inactivated Vaccines

        5.3.4. Subunit Vaccines

        5.3.5. Toxoid Vaccines

        5.3.6. DNA Vaccines

        5.3.7. Recombinant Vaccines

    5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017 to 2022

    5.5. Absolute $ Opportunity Analysis By Product Type, 2023 to 2033

6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Species Type

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Species Type, 2017 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Species Type, 2023 to 2033

        6.3.1. Canine

        6.3.2. Avian

        6.3.3. Feline

    6.4. Y-o-Y Growth Trend Analysis By Species Type, 2017 to 2022

    6.5. Absolute $ Opportunity Analysis By Species Type, 2023 to 2033

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2017 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Veterinary Clinics

        7.3.2. Veterinary Hospitals

        7.3.3. Veterinary Research Institutes

        7.3.4. Retail Pharmacies

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2017 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. East Asia

        8.3.5. South Asia

        8.3.6. Oceania

        8.3.7. Middle East & Africa (MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Product Type

        9.2.3. By Species Type

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Product Type

        9.3.3. By Species Type

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Product Type

        10.2.3. By Species Type

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Product Type

        10.3.3. By Species Type

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. France

            11.2.1.3. UK

            11.2.1.4. Italy

            11.2.1.5. Russia

            11.2.1.6. Spain

            11.2.1.7. BENELUX

            11.2.1.8. Rest of Europe

        11.2.2. By Product Type

        11.2.3. By Species Type

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Product Type

        11.3.3. By Species Type

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Product Type

        12.2.3. By Species Type

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Product Type

        12.3.3. By Species Type

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. Thailand

            13.2.1.2. Indonesia

            13.2.1.3. Malaysia

            13.2.1.4. India

            13.2.1.5. Rest of South Asia

        13.2.2. By Product Type

        13.2.3. By Species Type

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Product Type

        13.3.3. By Species Type

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Product Type

        14.2.3. By Species Type

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Product Type

        14.3.3. By Species Type

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. Northern Africa

            15.2.1.3. South Africa

            15.2.1.4. Rest of Middle East and Africa

        15.2.2. By Product Type

        15.2.3. By Species Type

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Product Type

        15.3.3. By Species Type

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Product Type

            16.1.2.2. By Species Type

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Product Type

            16.2.2.2. By Species Type

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Product Type

            16.3.2.2. By Species Type

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Product Type

            16.4.2.2. By Species Type

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Product Type

            16.5.2.2. By Species Type

            16.5.2.3. By Distribution Channel

    16.6. France

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Product Type

            16.6.2.2. By Species Type

            16.6.2.3. By Distribution Channel

    16.7. UK

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Product Type

            16.7.2.2. By Species Type

            16.7.2.3. By Distribution Channel

    16.8. Italy

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Product Type

            16.8.2.2. By Species Type

            16.8.2.3. By Distribution Channel

    16.9. Russia

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Product Type

            16.9.2.2. By Species Type

            16.9.2.3. By Distribution Channel

    16.10. Spain

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Product Type

            16.10.2.2. By Species Type

            16.10.2.3. By Distribution Channel

    16.11. BENELUX

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Product Type

            16.11.2.2. By Species Type

            16.11.2.3. By Distribution Channel

    16.12. China

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Product Type

            16.12.2.2. By Species Type

            16.12.2.3. By Distribution Channel

    16.13. Japan

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Product Type

            16.13.2.2. By Species Type

            16.13.2.3. By Distribution Channel

    16.14. South Korea

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Product Type

            16.14.2.2. By Species Type

            16.14.2.3. By Distribution Channel

    16.15. Thailand

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Product Type

            16.15.2.2. By Species Type

            16.15.2.3. By Distribution Channel

    16.16. Indonesia

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Product Type

            16.16.2.2. By Species Type

            16.16.2.3. By Distribution Channel

    16.17. Malaysia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Product Type

            16.17.2.2. By Species Type

            16.17.2.3. By Distribution Channel

    16.18. India

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Product Type

            16.18.2.2. By Species Type

            16.18.2.3. By Distribution Channel

    16.19. Australia

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Product Type

            16.19.2.2. By Species Type

            16.19.2.3. By Distribution Channel

    16.20. New Zealand

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Product Type

            16.20.2.2. By Species Type

            16.20.2.3. By Distribution Channel

    16.21. GCC Countries

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Product Type

            16.21.2.2. By Species Type

            16.21.2.3. By Distribution Channel

    16.22. Northern Africa

        16.22.1. Pricing Analysis

        16.22.2. Market Share Analysis, 2022

            16.22.2.1. By Product Type

            16.22.2.2. By Species Type

            16.22.2.3. By Distribution Channel

    16.23. South Africa

        16.23.1. Pricing Analysis

        16.23.2. Market Share Analysis, 2022

            16.23.2.1. By Product Type

            16.23.2.2. By Species Type

            16.23.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Product Type

        17.3.3. By Species Type

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Bayer Healthcare

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Vétoquinol S.A

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Boehringer Ingelheim

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Ceva Santé Animale

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Eli Lilly and Company

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Heska Corp.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Merck Animal Health

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Sanofi

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Virbac

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Pfizer

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Companion Animal Drugs Market

Published : February 2023

Healthcare

Companion Animal Vaccines Market

Published : January 2023

Explore Healthcare Insights

View Reports

Companion Animal Vaccines Market